Hangzhou Sumgen Biotech Co., Ltd.

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical Cancer
Phase 3
CD38Monoclonal antibody
Multiple MyelomaSystemic Lupus Erythematosus
Phase 1/2
LILRB4 (ILT3)Antibody–drug conjugate
Multiple Myeloma

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
March 2027 (2)
SanritatugPhase 2Antibody Mediated Rejection
Est. primary completion 2027-03-31 · NCT07764627 · CT.gov ↗
What to watch
SanritatugPhase 3Relapsed/Refractory Multiple Myeloma
Est. primary completion 2027-03-31 · NCT06508983 · CT.gov ↗
What to watch
April 2027 (1)
EnlonstobartPhase 1/2Locally Advanced Unresectable Esophageal Squamous Carcinoma
Est. primary completion 2027-04 · NCT06136988 · CT.gov ↗
What to watch
May 2027 (1)
SanritatugPhase 2Primary Immune Thrombocytopenia
Est. primary completion 2027-05-17 · NCT07710248 · CT.gov ↗
What to watch
September 2027 (2)
SG2918Phase 1/2Relapsed/Refractory Multiple Myeloma
Est. primary completion 2027-09-30 · NCT07454187 · CT.gov ↗
What to watch
SanritatugPhase 2Systemic Lupus Erythematosus (SLE)
Est. primary completion 2027-09-30 · NCT07447986 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
EnlonstobartPhase 1/2Advanced Hepatocellular Carcinoma (HCC)
Est. primary completion 2028-06-26 · NCT07282509 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.